Headlines about BioLineRx (NASDAQ:BLRX) have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research firm rates the sentiment of media coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. BioLineRx earned a daily sentiment score of 0.10 on Accern’s scale. Accern also gave news headlines about the biotechnology company an impact score of 45.5811594415964 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
Here are some of the news headlines that may have impacted Accern’s analysis:
- BioLineRx Ltd. (BLRX) Scheduled to Post Quarterly Earnings on Tuesday (americanbankingnews.com)
- BioLineRx to Report Third Quarter 2017 … (ih.advfn.com)
- BioLineRx to Report Third Quarter 2017 Results on November 21, 2017 (finance.yahoo.com)
- Zacks: Analysts Anticipate BioLineRx Ltd. (BLRX) Will Post Earnings of -$0.05 Per Share (americanbankingnews.com)
Several research analysts recently commented on the company. HC Wainwright reissued a “buy” rating on shares of BioLineRx in a research note on Tuesday, September 26th. Oppenheimer Holdings, Inc. reaffirmed a “buy” rating and set a $3.00 price objective on shares of BioLineRx in a research report on Tuesday, September 12th. Zacks Investment Research cut BioLineRx from a “hold” rating to a “sell” rating in a research report on Monday, August 14th. Roth Capital set a $3.00 price objective on BioLineRx and gave the stock a “buy” rating in a research report on Wednesday, August 9th. Finally, ValuEngine cut BioLineRx from a “hold” rating to a “sell” rating in a research report on Thursday, August 24th. One analyst has rated the stock with a sell rating and six have assigned a buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $2.88.
BioLineRx (NASDAQ BLRX) opened at $1.01 on Tuesday. BioLineRx has a 1 year low of $0.80 and a 1 year high of $1.38.
COPYRIGHT VIOLATION NOTICE: This report was originally posted by TrueBlueTribune and is owned by of TrueBlueTribune. If you are viewing this report on another publication, it was illegally copied and republished in violation of U.S. and international trademark and copyright laws. The original version of this report can be accessed at https://www.truebluetribune.com/2017/11/14/biolinerx-blrx-earning-somewhat-positive-media-coverage-analysis-shows.html.
BioLine RX Ltd is an Israel-based company engaged in the development of therapeutics, from preclinical-stage development to advanced clinical trials, for a range of medical needs. Its clinical therapeutic candidates under development consist of BL-1020 that is in Phase II/III clinical trials to improve cognitive function in schizophrenia patients; BL-1040, which is under pivotal CE-Mark registration trial for the prevention of cardiac remodeling following an acute myocardial infarction; BL-5010, which has completed Phase I/II clinical trials for non-surgical removal of skin lesions; BL-1021 that has completed Phase Ia clinical trial for the treatment of neuropathic pain or pain that results from damage to nerve fibers, and BL-7040, a synthetic oligonucleotide, which is in Phase II clinical trial for the treatment of inflammatory bowel disease.
Receive News & Ratings for BioLineRx Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLineRx Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.